For patients with non-small cell lung cancers marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of patients in a Phase I/II trial.
The University of Texas MD Anderson Cancer Center is committed to safely providing patient care and cancer screenings throughout the novel coronavirus (COVID-19) pandemic.
According to researchers from The University of Texas MD Anderson Cancer Center, the implementation of social distancing policies corresponded with significant reductions in transmission of the SARS-CoV-2 virus and reduced community mobility, both in the U.S. and globally, providing evidence that social distancing is a useful tool in preventing further spread of COVID-19.
The University of Texas MD Anderson Cancer Center and Sanofi today announced a five-year strategic collaboration to accelerate the development of investigational treatments, including targeted and immune therapies, for patients with cancer.
In the first study to look at objective measures of sedentary behavior and cancer mortality, researchers from The University of Texas MD Anderson Cancer Center found that greater inactivity was independently associated with a higher risk of dying from cancer.
A combination of two biomarkers was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors in patients with advanced bladder cancers.
MD Anderson and Philips today announced a collaboration to aid oncologists around the world to personalize therapy based on their patients’ genomic profiles, with the aim of improving patient care.
The University of Texas MD Anderson Cancer Center and Rakuten Medical, Inc. today announced a strategic alliance collaboration agreement to advance the development of new cancer therapies based on Rakuten Medical’s proprietary IlluminoxTM technology platform.
MD Anderson and Innovent Biologics have announced a strategic collaboration agreement to co-develop Innovent’s anti-PD-1 monoclonal antibody for treating rare cancers in the U.S.
Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers. Open-label Phase II study at MD Anderson reports on four cancer types.
Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function and recruiting them to the tumor, where they fuel growth and cancer progress.
A study led by The University of Texas MD Anderson Cancer Center furthered understanding about mitochondria, the cell components known as the “powerhouse of the cell.” Knowing more about the genome is crucial given that mitochondria play important roles in tumorigenesis.
Patients who had acupuncture during radiation reported less dry mouth symptoms up to 12 months after treatment
Researchers at The University of Texas MD Anderson Cancer Center have found that a protein involved in immune response to microbes, TBK1, also can fuel cancer development and suppress immune response to the disease.